HIV status determination among tuberculosis patients from California during 2008

Journal of Public Health Management and Practice

Volumn 19, Issue 2, 2013, Pages 169-177

  Kong, Darryl G ^a   Watt, James P ^a   Marks, Suzanne ^b   Flood, Jennifer ^a  

^a Division of Communicable Disease Control   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

HIV; Routine HIV testing; Tuberculosis

Indexed keywords

ADOLESCENT; ADULT; CALIFORNIA; COMORBIDITY; FEMALE; HEALTH SURVEY; HIV SEROPOSITIVITY; HUMAN; MALE; PROCEDURES; RETROSPECTIVE STUDY; TUBERCULOSIS; YOUNG ADULT; ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METHODOLOGY; UNITED STATES;

ADOLESCENT; ADULT; CALIFORNIA; COMORBIDITY; FEMALE; HIV SEROPOSITIVITY; HUMANS; MALE; POPULATION SURVEILLANCE; RETROSPECTIVE STUDIES; TUBERCULOSIS; YOUNG ADULT;

EID: 84873286811     PISSN: 10784659     EISSN: None     Source Type: Journal    
DOI: 10.1097/PHH.0b013e3182550a83     Document Type: Article

References (34)

1. Centers for DiseaseControl and Prevention.Tuberculosis and human immunodeficiency virus infection: recommendations of the Advisory Committee for the Elimination of Tuberculosis (ACET). MMWR Morb Mortal Wkly Rep. 1989;38: 236-250.
2. Centers for Disease Control and Prevention. Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the InfectiousDiseases Society of America. MMWR Recomm Rep. 2005;54: 1-81.
3. Centers for Disease Control and Prevention. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55: 1-17.
4. Centers for Disease Control and Prevention. Reported HIV status of tuberculosis patients - United States, 1993-2005. MMWR Morb Mortal Wkly Rep. 2007;56: 1103-1106.
5. Centers for DiseaseControl and Prevention. Mortality among patientswith tuberculosis and associations withHIVstatus - United States, 1993-2008. MMWR Morb Mortal Wkly Rep. 2010;59: 1509-1513.
6. Cayla JA, Caminero JA, Rey R, Lara N, Valles X, Galdos- Tanguis H. Current status of treatment completion and fatality among tuberculosis patients in Spain. Int J Tuberc Lung Dis. 2004;8: 458-464.
7. Horne DJ, Hubbard R, Narita M, Exarchos A, Park DR, Goss CH. Factors associated with mortality in patients with tuberculosis. BMC Infect Dis. 2010;10: 258.
8. Nahid P, Jarlsberg LG, Rudoy I, et al. Factors associated with mortality in patients with drug-susceptible pulmonary tuberculosis. BMC Infect Dis. 2011;11: 1.
9. Haar CH, Cobelens FG, Kalisvaart NA, van Gerven PJ, van der Have JJ. HIV-related mortality among tuberculosis patients in The Netherlands, 1993-2001. Int J Tuberc Lung Dis. 2007;11: 1038-1041.
10. Korenromp EL, Scano F,Williams BG, Dye C,Nunn P. Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clin Infect Dis. 2003;37: 101-112.
11. Burman W, Benator D, Vernon A, et al. Acquired rifamycin resistance with twice-weekly treatment ofHIV-related tuberculosis. Am J Respir Crit Care Med. 2006;173: 350-356.
12. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIVrelated tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet. 1999;353: 1843-1847.
13. Li J, Munsiff SS, Driver CR, Sackoff J. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000. Clin Infect Dis. 2005;41: 83-91.
14. Dheda K, Lampe FC, Johnson MA, Lipman MC. Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis. 2004;190: 1670-1676.
15. Nahid P, Gonzalez LC, Rudoy I, et al. Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med. 2007;175: 1199-1206.
16. Khan FA, Minion J, Pai M, et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis. 2010;50: 1288-1299.
17. King L, Munsiff SS, Ahuja SD. Achieving international targets for tuberculosis treatment success among HIV-positive patients inNew York City. Int J Tuberc Lung Dis. 2010;14: 1613-1620.
18. Centers for Disease Control and Prevention. Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep. 2005;54: 1-47.
19. Centers for Disease Control and Prevention. InstructionManual: Report of Verified Case of Tuberculosis. Washington, DC: US Department of Health and Human Services Centers for DiseaseControl and Prevention; 2009. http://www.cdc.gov/ tb/programs/rvct/InstructionManual.pdf. Accessed 1 June, 2011.
20. Rodger AJ, Story A, Fox Z, Hayward A. HIV prevalence and testing practices among tuberculosis cases in London: a missed opportunity for HIV diagnosis? Thorax. 2010;65: 63-69.
21. Stout JE, Ratard R, Southwick KL, Hamilton CD. Epidemiology of human immunodeficiency virus testing among patients with tuberculosis in North Carolina. South Med J. 2002;95: 231-238.
22. Asch SM, London AS, Barnes PF, Gelberg L. Testing for human immunodeficiency virus infection among tuberculosis patients in Los Angeles. Am J Respir Crit Care Med. 1997;155: 378-381.
23. Jenkins TC, Gardner EM, Thrun MW, Cohn DL, Burman WJ. Risk-based human immunodeficiency virus (HIV) testing fails to detect the majority of HIV-infected persons in medical care settings. Sex Transm Dis. 2006;33: 329-333.
24. Albalak R, O'Brien RJ, Kammerer JS, et al. Trends in tuberculosis/human immunodeficiency virus comorbidity, United States, 1993-2004. Arch Intern Med. 2007;167: 2443-2452.
25. Harris TG, Li J, Hanna DB, Munsiff SS. Changing sociodemographic and clinical characteristics of tuberculosis among HIV-infected patients, New York City, 1992-2005. Clin Infect Dis. 2010;50: 1524-1531.
26. Sturtevant D, Preiksaitis J, Singh A, et al. The feasibility of using an "opt-out" approach to achieve universal HIV testing of tuberculosis patients in Alberta. Can J Public Health. 2009;100: 116-120.
27. Burke RC, Sepkowitz KA, Bernstein KT, et al. Why don't physicians test for HIV? A review of the US literature. AIDS. 2007;21: 1617-1624.
28. Irwin KL, Valdiserri RO, Holmberg SD. The acceptability of voluntaryHIV antibody testing in theUnited States: a decade of lessons learned. AIDS. 1996;10: 1707-1717.
29. Lawn SD, Fraenzel A, Kranzer K, Caldwell J, Bekker LG, Wood R. Provider-initiated HIV testing increases access of patients with HIV-associated tuberculosis to antiretroviral treatment. S AfrMed J. 2011;101: 258-262.
30. Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States - an analysis of costeffectiveness. N Engl J Med. 2005;352: 586-595.
31. Bock NN, McGowan JE Jr, Blumberg HM. Few opportunities found for tuberculosis prevention among the urban poor. Int J Tuberc Lung Dis. 1998;2: 124-129.
32. Murphy DA,Mitchell R, Vermund SH, Futterman D. Factors associated with HIV testing among HIV-positive and HIVnegative high-risk adolescents: the REACH Study. Reaching for Excellence in Adolescent Care and Health. Pediatrics. 2002;110:e36.
33. Royce RA, Walter EB, Fernandez MI, Wilson TE, Ickovics JR, Simonds RJ. Barriers to universal prenatal HIV testing in 4 US locations in 1997. Am J Public Health. 2001;91: 727-733.
34. Anderson JE, Koenig LJ, Lampe MA, Wright R, Leiss J, Saul J. Achieving universal HIV screening in prenatal care in the United States: provider persistence pays off. AIDS Patient Care STDS. 2005;19: 247-252.